13 July 2017

Reminder of increased risk of meningococcal disease in winter

The Department of Health today reported that a middle-aged West Australian is currently recovering in hospital after being diagnosed with serogroup W meningococcal disease.

The disease usually occurs more commonly in winter and spring, and the current case is the fourth notified in the past three weeks, serving as a reminder of the increased risk over coming months.

The Department of Health has identified the person’s close contacts and provided them with information, and, where appropriate, antibiotics and a vaccine. This is to minimise the chance of further spread of the organism to others, should one or more of the contacts be carrying the strain that caused disease.

Meningococcal disease is an uncommon, life-threatening illness caused by a bacterial infection of the blood and/or the membranes that line the spinal cord and brain, and occasionally of other sites, such as the throat or large joints.

The incidence of the disease has decreased significantly in WA – down from a peak of 86 cases in 2000 to a low of 16 cases in 2013 – but may be increasing again.

Twenty-three cases were reported in 2016, and there have now been fourteen cases with disease onset during 2017.

Meningococcal bacteria are carried harmlessly in the back of the nose and throat by about 10-20 per cent of the population at any one time. Very rarely, the bacteria invade the bloodstream and cause serious infections.

Meningococcal bacteria are not easily spread from person-to-person. The bacterium is present in droplets discharged from the nose and throat when coughing or sneezing, but is not spread by saliva and does not survive more than a few seconds in the environment.  

Invasive meningococcal infection is most common in babies and young children, and older teenagers and young adults, but infection can occur at any age.

Symptoms may include high fever, chills, headache, neck stiffness, nausea and vomiting, drowsiness, confusion, and severe muscle and joint pains. Young children may not complain of symptoms, so fever, pale or blotchy complexion, vomiting, lethargy (blank staring, floppiness, inactivity, being hard to wake, or poor feeding) and rash are important signs.

Sometimes – but not always – symptoms may be accompanied by the appearance of a spotty red-purple rash that looks like small bleeding points beneath the skin or bruises.

Although treatable with antibiotics, meningococcal infection can progress very rapidly, so it is important that anyone experiencing these symptoms seeks medical attention promptly.

With appropriate treatment, most people with the disease recover, although around 5 per cent will die and around 15 per cent may experience complications such as hearing loss, or gangrene requiring skin grafts or amputations.

There are several types of meningococcal bacteria, but internationally disease is most commonly caused by what are known as serogroups A, B, C, W and Y organisms.

A vaccine to protect against the serogroup C type of meningococcal disease, which in the past was responsible for around 15 per cent of cases in WA, but is now very rare, is provided free to children at 12 months of age. A vaccine against serogroup B meningococcal infection, historically the most common type in WA, is available on prescription. Combination vaccines are also available that protect against four types of the organism (serogroups A, W and Y, in addition to serogroup C) that occur more commonly overseas.

Serogroups W and (to a lesser extent) Y meningococcal disease have increased significantly in frequency in some parts of Australia, including in WA, over the past three years.

Of the 23 cases reported in WA in 2016, six were serogroup B (the lowest number since 1990), two were serogroup Y and fourteen were serogroup W, up from the long term average of less than one serogroup W case per year. Of the fourteen cases notified to date in 2017, there have been seven serogroup W, four serogroup B, one serogroup C and one serogroup Y infection, along with a case in which the type could not be determined.

As a result of the recent increase in serogroup W disease in WA, a funded state-wide meningococcal ACWY vaccination program for adolescents aged 15 to 19 years commenced this year, and most of those eligible will receive vaccine at school during third term. Details are available at: http://healthywa.wa.gov.au/Articles/J_M/Meningococcal-vaccine

ENDS

Media contact: 9222 4333

Follow us on Twitter: @WAHealth